Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers
This cohort study compares incident and prevalent prescription rates of glucagon-like peptide-1 receptor agonists among adults with at least 1 obesity-related comorbidity and newly diagnosed cancer.
Authors
- Ania M. Jastreboff (ORCID: https://orcid.org/0000-0003-1446-0991)
- Joseph S. Ross (ORCID: https://orcid.org/0000-0002-9218-3320)
- Chungsoo Kim (ORCID: https://orcid.org/0000-0003-1802-1777)
- Yuan Lu (ORCID: https://orcid.org/0000-0001-5264-2169)
- Timothy J. Robinson (ORCID: https://orcid.org/0000-0003-0021-0668)
- Michaela A. Dinan (ORCID: https://orcid.org/0000-0003-4849-4743)
- Harlan M. Krumholz
Institutions
- Yale New Haven Hospital (US)
- Yale University (US)
- Yale New Haven Health System (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1001/jamaoncol.2025.4560
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29